NCT07257198RecruitingPhase 3
Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 2570 (estimated)
- First submitted
- 20 Nov 2025
- Start date
- 3 Mar 2026
- Primary completion date
- 1 Jan 2030
- Lead sponsor
- Montreal Heart Institute
- Diseases
- Coronary artery disease
- NCT number
- NCT07257198
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 2570
- From 3 Mar 2026 to the primary completion date, 1 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant indication for chronic oral anticoagulant;
- Concomitant non-coronary indication for dual antiplatelet therapy;
- Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;
- Previous hospitalization for MI, PCI, or CABG within 12 months;
Other illness
- Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
- Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
- Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;
Other
- Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
- Confirmed or suspected spontaneous coronary artery dissection;
- Unsuitability for either randomization treatment, based on the judgement of the treating physician
Who the study is looking for
- Age ≥18 years;
- Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
- Coronary angiogram performed;
- Planned for medical management alone, without revascularization;
- Willingness to participate and to attend study visits;
- Expected life expectancy ≥12 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Montreal Heart Institute Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.